Biora Therapeutics (BIOR) has provided an update.
Biora Therapeutics, Inc. is set to strengthen its financial posture with a series of Debt Exchange Transactions slated to conclude on March 12, 2024. The company will exchange $5,625,000 of its existing convertible senior notes for new notes and cash, while also providing purchase warrants for shares. This strategic move aims to enhance the company’s capital structure and comes alongside the announcement of monetizing its stake in Enumera Molecular, Inc., showcasing Biora’s proactive approach to managing its financial obligations and investments.
For detailed information about BIOR stock, go to TipRanks’ Stock Analysis page.
